Unicycive Therapeutics faces securities class action tied to oxylanthanum phosphate binder NDA statements

• Securities class action filed Sept. 3, 2026 in U.S. District Court, Northern District of California against Unicycive Therapeutics.
• Suit names certain officers, alleging federal securities law violations tied to public statements on its NDA for oxylanthanum carbonate.
• Claims focus on the phosphate binder’s use in treating hyperphosphatemia in chronic kidney disease patients on dialysis.
• Unicycive called the allegations meritless, signaling plans to fight the case.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Unicycive Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-104076), on September 28, 2026, and is solely responsible for the information contained therein.